Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin + psilocin
- Development stage
- Unknown
- Lead developer
- COMPASS Pathways
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Psilocybin and psilocin are psychedelic tryptamine compounds derived from Psilocybe cubensis mushrooms, currently being investigated by the Federal University of Latin American Integration for the treatment of treatment-resistant major depressive disorder (TRD). Psilocybin acts as a prodrug that is rapidly dephosphorylated into psilocin, which serves as a potent agonist at the serotonin 5-HT2A receptor. This activation is thought to promote neuroplasticity and alter functional connectivity in the brain, potentially leading to rapid and sustained antidepressant effects. The specific clinical trial context involves a Phase 2a pilot study evaluating the safety and efficacy of these compounds when administered in a psychotherapy-assisted framework, specifically exploring the impact of concurrent fluoxetine (an SSRI) on the psychedelic experience and therapeutic outcomes.
- Other names
- Psilocybe cubensis extractPsilocybin and PsilocynMagic mushrooms
02
Targets
SERT (Sodium-dependent serotonin transporter)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on psilocybin + psilocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin + psilocin.